Evaluation of the Functional Outcome of Hero Arm Prosthesis in Children After One Year of Use.
Launched by HOPITAUX DE SAINT-MAURICE · Oct 12, 2022
Trial Information
Current as of June 03, 2025
Unknown status
Keywords
ClinConnect Summary
Transverse forearm agenesis (TFA) is a sporadic, non-genetically based, mostly isolated congenital malformation. According to Froster-Iskenius U.G. \& Baird P.A, the incidence of this condition is estimated at 1.7 per 10,000 births. This condition is characterized by a lack of partial or complete development of a limb or limb segment. In transverse forearm agenesis (TFA), the majority of the damage occurs at the proximal-middle third of the limb.
In general, with the French administration, people with TFA are not considered to be disabled. However, this malformation can have a functional i...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Children between 7 and 16 years old
- • Children with a unilateral upper limb deformity
- • Children with a Hero Arm bionic myoelectric prosthesis, with or without another prosthesis
- • Children and parents who speak and understand French
- • No objection to data collection
- Exclusion Criteria:
- • Children with bilateral upper limb malformation
- • Children with cognitive disorders who are not able to learn to use a myoelectric prosthesis
About Hopitaux De Saint Maurice
Hôpitaux de Saint-Maurice is a leading healthcare institution dedicated to providing high-quality medical care and advancing clinical research in various fields. Located in France, the facility is committed to improving patient outcomes through innovative therapies and evidence-based practices. With a multidisciplinary team of experienced healthcare professionals, Hôpitaux de Saint-Maurice actively sponsors and conducts clinical trials that aim to explore new treatment modalities, enhance patient safety, and contribute to the global body of medical knowledge. Their focus on patient-centered research ensures that trials are designed with the utmost consideration for participant well-being and ethical standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Saint Maurice, Ile De France, France
Patients applied
Trial Officials
Nathaly QUINTERO-PRIGENT, Doctor
Study Director
Centre de Référence pour les Anomalies des Membres (CEREFAM)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials